How does polivy impact patient's immune system?

Short answer: Polivy (polatuzumab vedotin) mainly reduces B cells, so it can dampen humoral (antibody-mediated) immunity and raise infection risk. It’s often used with other chemotherapy and an anti-CD20 antibody, which can add to immune suppression.

What Polivy does to the immune system
- Target: Polatuzumab vedotin is an antibody-drug conjugate that binds CD79b on B cells.
- Mechanism: After binding, it’s internalized and releases a toxin (MMAE) inside the B cell, killing the B cell.
- Immune effect: This leads to depletion of normal B cells as well as malignant ones, which reduces antibody production (humoral immunity) and can lower immunoglobulin levels (hypogammaglobulinemia).
- Infection risk: With fewer B cells and when combined with other chemotherapies (and rituximab, if used), patients are at higher risk for infections, including bacterial and viral infections. Neutropenia (a drop in another type of immune cell) can also occur with the chemo backbone.
- Vaccine response: The ability to respond to vaccines (especially new or inactivated vaccines) can be diminished during treatment. Live vaccines are generally avoided during therapy.

What this means for management and monitoring (general considerations)
- Monitoring: Expect regular blood counts (to watch for neutropenia and other cytopenias) and, when appropriate, immunoglobulin levels. Your clinician may check B-cell counts too.
- Infections: Report fever, cough, shortness of breath, urinary symptoms, or any sign of infection promptly. Treat infections early; some patients may need antibiotics or hospital care.
- Vaccines: Live vaccines are usually avoided during treatment. If possible, discuss timing of vaccines (ideally before starting Polivy) with your oncology team.
- Immunoglobulin support: If you have severe or recurrent infections or very low IgG/other immunoglobulins, IVIG (intravenous immunoglobulin) therapy may be considered.
- Dose adjustments and planning: Because Polivy is used with other immune-suppressing therapies (like bendamustine and rituximab in BR, or R-CHP in some regimens), the combined effect on the immune system is greater. Your doctor may adjust monitoring and supportive care accordingly.

If you’d like, tell me:
- Are you asking about Polivy for yourself or someone else?
- Which regimen it’s being given with (e.g., Polivy + BR or Polivy + R-CHP)?
- Any prior history of infections or immune issues?

I can tailor the information to that scenario and discuss specific precautions or monitoring questions with you. This is general information and not a substitute for medical advice from a clinician.